Bradbury Group has finalized an RM150 million capital commitment to establish the Crewstone Bradbury Penjana Fund. The investment vehicle operates within the framework of the Malaysian Government’s Dana Penjana Nasional matching initiative to deploy capital into regional technology enterprises.
Bradbury Group has committed to a US$20 million strategic investment in Mirror Biologics, Inc. The allocation successfully closes out the issuer’s US$30 million Series A funding round. Capital is directed toward the advancement of clinical trials and the expansion of proprietary biomanufacturing capabilities.
Tron Bradbury Energy has initiated the development of a regional electric vehicle (EV) manufacturing and distribution hub within the Malaysia Vision Valley. The infrastructure project is advancing with the institutional support and recognition of the Malaysian Investment Development Authority (MIDA).
Bradbury has executed a US$3 million strategic investment in IGC Pharma (NYSE American: IGC) via an unregistered private placement of common stock. The capital allocation is mandated to support the advancement of the issuer’s clinical pipeline, including ongoing Alzheimer’s disease trials, and general corporate working capital.
Bradbury has entered into a memorandum of understanding to explore co-investment frameworks with a regulated sovereign wealth platform in Southeast Asia, focused on infrastructure and energy transition mandates.
Lorem ipsum dolor sit amet, consectet adipiscing elit,sed do eiusm por incididut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercita ullamco Lorem ipsum dolor sit amet, consectet adipiscing elit,sed do eiusm
